Abstract
Breast cancer is among the most frequently occurring cancer for women globally. Conventional therapies for breast cancer are found to be expensive and cause severe aftereffects; further increasing drug resistance is also attracting the interest of researchers to explore novel therapeutic strategies to treat breast cancer. Among the cutting-edge approaches, several therapeutic peptides that target and destroy tumour cells have attracted much concern. Short chains of amino acids known as therapeutic peptides have a high affinity for binding and regulating a specific protein interaction. A reliable way to get around the issues with other therapies is through targeted therapy. Additionally, it enables medications to selectively localize at predetermined locations. Therapeutic peptides are an innovative and promising method for treating solid tumours, notably breast cancer. The aim of this review article is to give an extensive and informative overview of therapeutic peptides and how they are used to treat breast cancer. Research into new, efficient therapeutic approaches for breast cancer treatment can be supported by the development of beneficial therapeutic technologies, like therapeutic peptides and their different anti-cancerous potential against tumor cells.
Graphical Abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmed S, Mirzaei H, Aschner M et al (2021) Marine peptides in breast cancer: therapeutic and mechanistic understanding. Biomed Pharmacother 142:112038
Al Bitar S, Gali-Muhtasib H (2019) The role of the cyclin dependent kinase inhibitor p21cip1/waf1 in targeting cancer: molecular mechanisms and novel therapeutics. Cancers 11(10):1475
Alonso-Álvarez S, Pardal E, Sánchez-Nieto D et al (2017) Plitidepsin: design, development, and potential place in therapy. Drug Des Devel Ther 11:253
Apostolou P, Papasotiriou I (2017) Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer 331–335.
Arens R, van Hall T, van der Burg SH et al (2013) Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol. https://doi.org/10.1016/j.smim.2013.04.008
Atapour A, Negahdaripour M, Ghasemi Y et al (2020) In silico designing a candidate vaccine against breast cancer. Int J Pept Res Ther 26(1):369–380. https://doi.org/10.1007/s10989-019-09843-1
Badve S, Harikrishna N (2012) Breast-cancer stem cells—beyond semantics. Lancet Oncol. https://doi.org/10.1016/S1470-2045(11)70191-7
Bailur JK, Gueckel B, Derhovanessian E et al (2015) Presence of circulating Her2-reactive CD8+ T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. BCR. https://doi.org/10.1186/s13058-015-0541-z
Barriga V, Kuol N, Nurgali K et al (2019) The complex interaction between the tumor micro-environment and immune checkpoints in breast cancer. Cancers. https://doi.org/10.3390/cancers11081205
Beheshtirouy S, Mirzaei F, Eyvazi S et al (2021) Recent advances in therapeutic peptides for breast cancer treatment. Curr Protein Pept Sci. https://doi.org/10.2174/1389203721999201117123616
Benavides LC, Sears AK, Gates JD et al (2011) Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines. https://doi.org/10.1586/erv.10.167
Benvenuto JA, Newman RA, Bignami GS et al (1992) Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs 10(2):113–117
Bhattacharjee T, Adhikari S, Bhattacharjee S et al (2022a) Exploring dithiolate-amine binary ligand systems for the supramolecular assemblies of Ni (II) coordination compounds: crystal structures, theoretical studies, cytotoxicity studies, and molecular docking studies. Inorg Chim Acta 543:121157
Bhattacharjee T, Adhikari S, Sheikh AH et al (2022b) Syntheses, crystal structures, theoretical studies, and anticancer properties of an unsymmetrical schiff base ligand N-2-(6-methylpyridyl)-2-hydroxy-1-naphthaldimine and its Ni (II) complex. J Mol Struct. https://doi.org/10.1016/j.molstruc.2022.133717
Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer. https://doi.org/10.1186/1476-4598-10-3
Capek I (2017) Polymer decorated gold nanoparticles in nanomedicine conjugates. Adv Colloid Interface Sci 249:386–399
Carmichael Mark G, Benavides LC, Holmes JP et al (2010) Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. https://doi.org/10.1002/cncr.24756
Chang HN, Liu BY, Qi YK et al (2015) Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew Chem Int Ed 54(40):11760–11764
Chu Y, Zhang Y, Wang Q et al (2022) A transformer-based model to predict peptide–HLA class I binding and optimize mutated peptides for vaccine design. Nat Mach Intell 4(3):300–311
Coleman JE, de Silva ED, Kong F et al (1995) Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 51(39):10653–10662
Cooper BM, Iegre J, O’Donovan DH et al (2021) Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs). Chem Soc Rev 50(3):1480–1494
Criscitiello C (2012a) Tumor-associated antigens in breast cancer. Basel. https://doi.org/10.1159/000342164
de Paula P, da Luz FACL et al (2015) Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv. https://doi.org/10.1016/j.biotechadv.2015.10.013
Demissei BD, Freedman G, Feigenberg SJ et al (2019) Early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy for breast cancer, lung cancer, and lymphoma. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2018.11.013
Dong P, Maddali MV, Srimani JK et al (2014) Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control. Commun Nat. https://doi.org/10.1038/ncomms5750
Donia MS, Wang B, Dunbar DC et al (2008) Mollamides B and C, cyclic hexapeptides from the Indonesian tunicate Didemnum molle. J Nat Prod 71(6):941–945
Draeger LJ, Mullen GP (1994) Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J Biol Chem 269(3):1785–1793
Elbachiri M, Fatima S, Bouchbika Z et al (2017) Breast cancer in men: about 40 cases and literature review. Pan Afr Med J 28:287–287
Elizalde PV, Russo RI, Chervo MF et al (2016) ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer 23(12):T243–T257
Enciu A-M, Radu E, Popescu ID et al (2018) Targeting CD36 as biomarker for metastasis prognostic: how far from translation into clinical practice? Biomed Res Int. https://doi.org/10.1155/2018/7801202
Eroles P, Ana Bosch J, Pérez-Fidalgo A et al (2012b) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. https://doi.org/10.1016/j.ctrv.2011.11.005
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210
Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol. https://doi.org/10.1038/nri1150
Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Disco Today 20:122–128
Freitas VM, Rangel M, Bisson LF et al (2008) The geodiamolide H, derived from brazilian sponge Geodia corticostylifera, regulates actin cytoskeleton, migration and invasion of breast cancer cells cultured in three-dimensional environment. J Cell Physiol 216(3):583–594
Gao X, Qiong-Zhu D (2020) Advance in metabolism and target therapy in breast cancer stem cells. World J Stem Cells 12:1295.
Giorello L, Clerico L, Pescarolo MP et al (1998) Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 58:3654–3659
Girigoswami K, Saini D, Girigoswami A (2021) Extracellular matrix remodeling and development of cancer. SCRR. https://doi.org/10.1007/s12015-020-10070-1
Golubnitschaja O, Debald M, Yeghiazaryan K et al (2016) Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol 37:12941–12957
Green AR, Aleskandarany MA, Agarwal D et al (2016) MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer. https://doi.org/10.1038/bjc.2016.46
Hayashi MA, Ducancel F, Konno K (2012c) Natural peptides with potential applications in drug development, diagnosis, and/or biotechnology. Hindawi
Henninot A, Collins JC, Nuss JM (2018) The current state of peptide drug discovery: back to the future? J Med Chem 61:1382–1414
Holmes Jarrod P, Benavides LC, Gates JD et al (2008) Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. Am J Clin Oncol. https://doi.org/10.1200/JCO.2007.15.7842
Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778(2):357–375
Howell A, Anderson AS, Clarke RB et al (2014) Risk determination and prevention of breast cancer. BCR 16(5):1–9. https://doi.org/10.1186/s13058-014-0446-2
Hsu KC, Li-Chan EC, Jao CL (2011) Antiproliferative activity of peptides prepared from enzymatic hydrolysates of tuna dark muscle on human breast cancer cell line MCF-7. Food Chem 126(2):617–622
Jalota-Badhwar A, Kaul-Ghanekar R, Mogare D et al (2007) SMAR1-derived P44 peptide retains its tumor suppressor function through modulation of p53. J Biol Chem 282(13):9902–9913
Jantaruk P, Roytrakul S, Sitthisak S et al (2017) Potential role of an antimicrobial peptide, KLK in inhibiting lipopolysaccharide-induced macrophage infammation. PLoS ONE 12(8):e0183852
Jothimani G, Sriramulu S, Chabria Y et al (2018) A review on theragnostic applications of microRNAs and long non-coding RNAs in colorectal cancer. Curr Top Med Chem 18(30):2614–2629
Karami Fath M, Babakhaniyan K, Zokaei M et al (2022) Anti-cancer peptide-based therapeutic strategies in solid tumors. Cell Mol Biol Lett 27:33. https://doi.org/10.1186/s11658-022-00332-w
Karkada M, Weir GM, Quinton T et al (2010) A liposome-based platform, VacciMax®, and its modified water-free platform DepoVax™ enhance efficacy of in vivo nucleic acid delivery. Vaccine. https://doi.org/10.1016/j.vaccine.2010.07.025
Karkada M, Quinton T, Blackman R et al (2013) Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory/suppressor cell proliferation and tumor infiltration. Int Sch Res Not. https://doi.org/10.1155/2013/753427
Karyampudi L, Formicola C, Erskine CL et al (2010) A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88–102. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-09-2781
Kim SJ, Shawn CO (2020) Hyaluronic acid binding to CD44S is indiscriminate of molecular weight. Biochim Biophys Acta Biomembr. https://doi.org/10.1016/j.bbamem.2020.183348
Kim Y-J, Kim JY, Lee N et al (2017) Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem Biophys Res Commun. https://doi.org/10.1016/j.bbrc.2017.03.164
Ko CCH, Chia WK, Selvarajah GT et al (2020) The role of breast cancer stem cell-related biomarkers as prognostic factors. Diagnostics. https://doi.org/10.3390/diagnostics10090721
Kohlgraf KG, Gawron AJ, Higashi M et al (2004) Tumor-specific immunity in MUC1. Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother. https://doi.org/10.1007/s00262-004-0557-1
Ladjemi MZ, Jacot W, Chardès T et al (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-010-0869-2
Li J, Liu G, Ji Y et al (2019) Switching to anastrozole plus goserelinvs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial. Cancer Manag Res 299–307.
Li CM, Haratipour P, Lingeman RG et al (2021) Novel peptide therapeutic approaches for cancer treatment. Cells 11:2908. https://doi.org/10.3390/cells10112908
Liu X, JiujiaoGao YS et al (2017) Mutation of N-linked glycosylation in EpCAM affected cell adhesion in breast cancer cells. Biol Chem. https://doi.org/10.1515/hsz-2016-0232
Malayaperumal S, Sriramulu S, Jothimani G et al (2021) A review of AEG-1 oncogene regulating MicroRNA expression in colon cancer progression. EMIDDT 21(1):27–34
Malonis RJ, Lai JR, Vergnolle O (2019) Peptide-based vaccines: current progress and future challenges. Chem Rev 120(6):3210–3229
Marqus S, Pirogova E, Piva TJ (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24(1):1–15
Marshall JL, Gulley JL, Arlen PM et al (2005) Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen–expressing carcinomas. Am J Clin Oncol. https://doi.org/10.1200/JCO.2005.10.206
Matsui Y, Halter SA, Holt JT et al (1990) Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice. Cell. https://doi.org/10.1016/0092-8674(90)90077-R
Mazumder S, Du Pree E, Almasan A (2004) A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets 4(1):65–75
Mehdizadeh A, Somi MH, Darabi M et al (2017) Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2. Artif Cells Nanomed Biotechnol. https://doi.org/10.1080/21691401.2016.1269117
Melchor L, Benítez J (2013) The complex genetic landscape of familial breast cancer. Hum 132(8):845–863. https://doi.org/10.1007/s00439-013-1299-y
Miller MJ, Foy KC, Kaumaya PT (2013) Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 15(82):166–176
Mittendorf Elizabeth A, Clifton GT, Holmes JP et al (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. https://doi.org/10.1002/cncr.26574
Mizejewski G, Muehlemann M, Dauphinee M (2006) Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis. Chemotherapy 52(2):83–90
Mohit E, Hashemi A, Allahyari M (2014) Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol. https://doi.org/10.1586/1744666X.2014.916211
Morita R, Hirohashi Y, Sato N (2012) Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity. Immunotherapy. https://doi.org/10.2217/imt.12.116
Myc Lukasz A, Gamian A, Myc A (2011) Cancer vaccines. Any future? Arch Immunol Ther Exp. https://doi.org/10.1007/s00005-011-0129-y
Nakatskasa K, Koyama H, Ouchi Y et al (2019) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab. https://doi.org/10.1007/s00774-018-0917-0
Narayan S (2021) Challenges and future opportunities of nanomedicine in cancer therapy. In Nanomedicine for cancer diagnosis and therapy. Springer, Singapore 221–249
Nath J, Paul R, Ghosh SK et al (2020) Drug repurposing and relabeling for cancer therapy: emerging benzimidazole antihelminthics with potent anticancer effects. Life Sci 258:118189
Nath P, Datta A, Adhikari S (2022) Recent advances of metal-based anticancer agents and their in vivo potential against various types of malignancies. In: Pathak S, Banerjee A, Bisgin A (eds) Handbook of animal models and its uses in cancer research. Springer, Singapore
Nazıroğlu M, Tokat S, Demirci S (2012) Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+ signaling molecular pathways in breast cancer. J Recept Signal Transduct 32(6):290–297. https://doi.org/10.3109/10799893.2012.737002
Nilendu P, Kumar A, Kumar A et al (2018) Breast cancer stem cells as last soldiers eluding therapeutic burn: a hard nut to crack. Int J Cancer. https://doi.org/10.1002/ijc.30898
Orafaie A, Bahrami AR, Matin MM (2021) Use of anticancer peptides as an alternative approach for targeted therapy in breast cancer: a review. Nanomedicine 16(5):415–433
Ortega Miguel A, Fraile-Martínez O, Asúnsolo Á et al (2020) Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR. J Oncol. https://doi.org/10.1155/2020/9258396
Patil R, Clifton GT, Holmes JP et al (2010) Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg. https://doi.org/10.1016/j.jamcollsurg.2009.10.022
Payandeh Z, Rajabibazl M, Mortazavi Y et al (2018) Ofatumumab monoclonal antibody afnity maturation through in silico modeling. Iran Biomed J 22(3):180
Payandeh Z, Rajabibazl M, Mortazavi Y et al (2019) Afnity maturation and charac- terization of the ofatumumab monoclonal antibody. J Cell Biochem 120(1):940–950
Peoples George E, Holmes JP, Human MT et al (2008) Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-07-1448
Perez EA, Hillman DW, Fishkin PA et al (2005) Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23(3):257–261
Perret R, Sierro SR, Botelho NK et al (2013) Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity adjuvants modulate antitumor Teff: Treg ratios. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-13-0875
Qi CF, Liscia DS, Normanno N et al (1994) Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer. https://doi.org/10.1038/bjc.1994.174
Quail DQ, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med. https://doi.org/10.1038/nm.3394
Rahman M, Zaki Ahmad M, Kazmi I et al (2012) Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr Drug Discov Technol 9(4):319–329
Raucher D (2019) Tumor targeting peptides: novel therapeutic strategies in glioblastoma. Curr Opin Pharmacol 47:14–19
Rueda OM, Sammut SJ, Seoane JA et al (2019) Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature 567(7748):399–404. https://doi.org/10.1038/s41586-019-1007-8
Salomon DS, Normanno N, Ciardiello F et al (1995) The role of amphiregulin in breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/BF00682718
Sandgren Eric P, Luetteke NC, Palmiter RD et al (1990) Overexpression of TGFα in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell. https://doi.org/10.1016/0092-8674(90)90075-P
Sani M-A, Separovic F (2016) How membrane-active peptides get into lipid membranes. Acc Chem Res 49(6):1130–1138
Sato AK, Viswanathan M, Kent RB et al (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17(6):638–642
Scott DA, Drake RR (2019) Glycosylation and its implications in breast cancer. Expert Rev Proteom 16(8):665–680
Sears AK, Perez SA, Clifton GT et al (2011) AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert OpinBiolTher. https://doi.org/10.1517/14712598.2011.616889
Senapati S, Mahanta AK, Kumar S et al (2018) Controlled drug delivery vehicles for cancer treatment and their perfor- mance. Signal Transduct Target Ther 3(1):1–19
Sharma P, Kaur H, Kehinde BA et al (2020) Food-derived anticancer peptides: a review. Int J Pept Res Ther 27(1):55–70. https://doi.org/10.1007/s10989-020-10063-1
Sharmiladevi P, Girigoswami K, Haribabu V et al (2021) Nano-enabled theranostics for cancer. Adv Mater 2(9):2876–2891
Shetty SR, Yeeravalli R, Bera T et al (2021) Recent advances on epidermal growth factor receptor as a molecular target for breast cancer therapeutics. Anticancer Agents Med Chem 21(14):1783–1792
Shin T-H, Sung E-S, Kim Y-J et al (2014) Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 13(3):651–661
Singh Pankaj K, Michael A (2006) Hollingsworth. Cell surface-associated mucins in signal transduction. Trends Cell Biol. https://doi.org/10.1016/j.tcb.2006.07.006
Song K, Maryam F (2021) Signaling pathways governing breast cancer stem cells behavior. Stem Cell Res Ther. https://doi.org/10.1186/s13287-021-02321-w
Sotiriadou NN, Kallinteris NL, Gritzapis AD et al (2007) Ii-Key/HER-2/neu (776–90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-006-0213-z
Soucek L, Gerard IE (2010) The ups and downs of Myc biology. Curr Opin Genet Dev. https://doi.org/10.1016/j.gde.2009.11.001
Soudy R, Gill A, Sprules T et al (2011) Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J Med Chem. https://doi.org/10.1021/jm200750x
Suárez Y, González L, Cuadrado A et al (2003) Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2(9):863–872
Suman A, Bhattacharjee T, Butcher RJ et al (2019) Synthesis and characterization of mixed-ligand Zn (II) and Cu(II) complexes including polyamines and dicyano-dithiolate(2-): in vitro cytotoxic activity of Cu(II) compounds. Inorg Chim Acta 498:119098. https://doi.org/10.1016/j.ica.2019.119098
Takahashi R, Toh U, Nobutaka I, Wakuma et al (2014) Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/bcr3685
Tan S, Yamashita A, Gao SJ et al (2019) Hyaluronic acid hydrogels with defined crosslink density for the efficient enrichment of breast cancer stem cells. Acta Biomater. https://doi.org/10.1016/j.actbio.2019.05.040
Tecalco-Cruz AC, Ríos-López DG, Vázquez-Victorio G et al (2018) Transcriptional cofactors Ski and SnoN are major regulators of the TGF-β/Smad signaling pathway in health and disease. Signal Transduct Target Ther 3(1):15
Teeuwssen M, Riccardo F (2019) Cell heterogeneity and phenotypic plasticity in metastasis formation: the case of colon cancer. Cancers. https://doi.org/10.3390/cancers11091368
Thrivikraman G, Boda SK, Basu B (2018) Unraveling the mechanistic effects of electric field stimulation towards directing stem cell fate and function: a tissue engineering perspective. Biomaterials 150:60–86
Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. https://doi.org/10.1155/2012/967347
Tobias J, Drinić M, Högler S et al (2022a) Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Transl Oncol 19:101378
Tobias J, Garner-Spitzer E, Drinić M et al (2022b) Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open 7(1):100361
Tomita H, Kaori T, Takuji T et al (2016) Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7:11018
Tornesello AL, Borrelli A, Buonaguro L et al (2020) Antimicrobial peptides as anticancer agents: functional properties and biological activities. Molecules 25(12):2850
Wang S, Liu H, Zhang X et al (2015) Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 6(7):480–503
Wang L, Wang N, Zhang W et al (2022) Therapeutic peptides: current applications and future directions. Sig Transduct Target Ther 7:48. https://doi.org/10.1038/s41392-022-00904-4
Wei Y, Davis J, Bina WF (2012) Ambient air pollution is associated with the increased incidence of breast cancer in US. Int J Environ Health Res. https://doi.org/10.1080/09603123.2011.588321
Wiedermann C, Wiltschke JJ et al (2010) A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-009-0666-9
Wiedermann U, Davis AB, Zielinski CC (2013) Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-013-2410-8
Xie M, Liu D, Yang Y (2020) Anti-cancer peptides: classification, mechanism of action, reconstruction and modification. Open Biol 10(7):200004
Xu X, Zhang M, Xu F et al (2020) Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. https://doi.org/10.1186/s12943-020-01276-5
Yamazaki T, Wennerberg E, Hensler M et al (2021) LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. Oncoimmunology 10(1):1962592
Yang F, Jing Xu, Tang L et al (2017) Breast cancer stem cell: the roles and therapeutic implications. Cell Mol Life Sci. https://doi.org/10.1007/s00018-016-2334-7
Yin L, Duan J-J, Bian X-W et al (2020) Triple-negative breast cancer molecular subtyping and treatment progress. BCR. https://doi.org/10.1186/s13058-020-01296-5
Zhang Y, Chaoran Y (2020) Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer. BMC Cancer. https://doi.org/10.1186/s12885-020-07034-6
Zhang JY, Fu LW (2008) Advance of several types of important marine antitumor drugs. Yao Xue Xue Bao Acta Pharmaceutica Sinica 43(5):435–442
Zhang B, Zhang X (2013) Separation and nanoencapsulation of antitumor polypeptide from Spirulina platensis. Biotechnol Prog 29(5):1230–1238
Zhao H, Qin X, Yang D et al (2017) The development of activatable lytic peptides for targeting triple negative breast cancer. Cell Death Discov 3(1):1–8
Zheng L-H, Wang Y-J, Sheng J et al (2011) Antitumor peptides from marine organisms. Mar Drugs 9(10):1840–1859
Zhong J, Chau Y (2008) Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase. Mol Cancer Ther 7(9):2933–2940
Zhou J, Chen Q, Zou Y et al (2019) Stem cells and cellular origins of breast cancer: updates in the rationale, controversies, and therapeutic implications. Front Oncol. https://doi.org/10.3389/fonc.2019.00820
Acknowledgements
The authors are thankful to the Chettinad Academy of Research and Education (CARE), Chennai, India.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
The study was designed, and the manuscript was written by AD, SA, DD and reviewed and edited by SA, AB, SP, NB, IB, AB and SP.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Das, A., Adhikari, S., Deka, D. et al. An Updated Review on Recent Advances in the Usage of Novel Therapeutic Peptides for Breast Cancer Treatment. Int J Pept Res Ther 29, 32 (2023). https://doi.org/10.1007/s10989-023-10503-8
Accepted:
Published:
DOI: https://doi.org/10.1007/s10989-023-10503-8